AstraZeneca will soon start a phase 3 trial of a subcutaneous version of its anti-CD19 T-cell engager.
ApexOnco Front Page
Recent articles
A son of glembatumumab vedotin has just started its phase 1 study.
But the overall survival benefit in prostate cancer is still driven by HRR mutations.
Phase 1 data give investors a benchmark for mevrometostat's pivotal Mevpro-1 trial.
AbbVie follows Gilead in throwing Xilio a lifeline.
The deal isn’t done, but would be Merck’s biggest oncology buy.
Padcev still looks good in first-line bladder, but Pfizer hopes to make a mark in muscle-invasive disease.
Orca-T is said to hit in a pivotal trial, but the comparator regimen could be debated.
